Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 21, 2024 (filed on Mar 25, 2024)Insider Name:Garber Alan MOwnership Type:Direct OwnershipSecurities:Option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-23,491Price:--
-
Mar 21, 2024 (filed on Mar 25, 2024)Insider Name:Garber Alan MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-19,205Price:$24.01
-
Mar 21, 2024 (filed on Mar 25, 2024)Insider Name:Garber Alan MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:23,491Price:$19.57
-
Feb 23, 2024 (filed on Feb 27, 2024)Insider Name:Peterson Amy C.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:82,121Price:--
-
Feb 23, 2024 (filed on Feb 27, 2024)Insider Name:Aftab DanaOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:63,350Price:--
-
Feb 23, 2024 (filed on Feb 27, 2024)Insider Name:Morrissey MichaelOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:241,670Price:--
-
Feb 23, 2024 (filed on Feb 27, 2024)Insider Name:Senner Christopher J.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:82,121Price:--
-
Feb 23, 2024 (filed on Feb 27, 2024)Insider Name:Hessekiel JeffreyOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:63,350Price:--
-
Feb 23, 2024 (filed on Feb 27, 2024)Insider Name:Haley Patrick J.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-47,020Price:$21.45
-
Feb 23, 2024 (filed on Feb 27, 2024)Insider Name:Haley Patrick J.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:63,350Price:--
Filings by filing date
-
Mar 21, 2024 (filed on Mar 25, 2024)Insider Name:Garber Alan MOwnership Type:Direct OwnershipSecurities:Option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-23,491Price:--
-
Mar 21, 2024 (filed on Mar 25, 2024)Insider Name:Garber Alan MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-19,205Price:$24.01
-
Mar 21, 2024 (filed on Mar 25, 2024)Insider Name:Garber Alan MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:23,491Price:$19.57
-
Feb 23, 2024 (filed on Feb 27, 2024)Insider Name:Peterson Amy C.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:82,121Price:--
-
Feb 23, 2024 (filed on Feb 27, 2024)Insider Name:Aftab DanaOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:63,350Price:--
-
Feb 23, 2024 (filed on Feb 27, 2024)Insider Name:Morrissey MichaelOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:241,670Price:--
-
Feb 23, 2024 (filed on Feb 27, 2024)Insider Name:Senner Christopher J.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:82,121Price:--
-
Feb 23, 2024 (filed on Feb 27, 2024)Insider Name:Hessekiel JeffreyOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:63,350Price:--
-
Feb 23, 2024 (filed on Feb 27, 2024)Insider Name:Haley Patrick J.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-47,020Price:$21.45
-
Feb 23, 2024 (filed on Feb 27, 2024)Insider Name:Haley Patrick J.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:63,350Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1851 Harbor Bay Parkway ALAMEDA CA 94502 |
Tel: | N/A |
Website: | https://www.exelixis.com |
IR: | See website |
Key People | ||
Michael M. Morrissey President, Chief Executive Officer, Director | Christopher J. Senner Chief Financial Officer, Executive Vice President | Dana T. Aftab Executive Vice President - Discovery and Translational Research, Chief Scientific Officer |
Jeffrey J. Hessekiel Executive Vice President, General Counsel, Secretary | Patrick Joseph Haley Executive Vice President - Commercial | Amy Peterson Executive Vice President, Product Development & Medical Affairs and Chief Medical Officer | Peterson C. Peterson Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer |
Business Overview |
Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension. |
Financial Overview |
For the fiscal year ended 29 December 2023, Exelixis Inc revenues increased 14% to $1.83B. Net income increased 14% to $207.8M. Revenues reflect CABOMETYX segment increase of 17% to $1.61B, License revenues segment increase of 10% to $178.6M, U.S segment increase of 16% to $1.65B, Japan segment increase of 37% to $39.5M. Net income also reflects Interest Income increase from $33.1M to $86.5M (income). |
Employees: | 1,310 as of Dec 29, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $5,924M as of Dec 29, 2023 |
Annual revenue (TTM): | $1,830M as of Dec 29, 2023 |
EBITDA (TTM): | $196.60M as of Dec 29, 2023 |
Net annual income (TTM): | $207.77M as of Dec 29, 2023 |
Free cash flow (TTM): | $292.86M as of Dec 29, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 303,194,259 as of Jan 29, 2024 |
Index Membership: | S&P 400 Mid Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |